Policy | April 03, 2026
EMA moves to cut animal testing with “virtual control groups” in preclinical research
The approach, which could significantly reduce the number of rats used in certain dose-range finding studies
The approach, which could significantly reduce the number of rats used in certain dose-range finding studies
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The center brings together hands on technology demonstrations, application expertise, and commercial operations
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
Allergan also presented new insights on the growing population of patients on GLP-1 agonists for weight loss who are seeking aesthetic treatments
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
Subscribe To Our Newsletter & Stay Updated
